Natera shares are trading higher after the company announced the publication of three peer-reviewed papers, resulting in over 85 peer-reviewed publications on its cancer diagnostic test Signatera
Portfolio Pulse from Benzinga Newsdesk
Natera's stock is rising following the publication of three new peer-reviewed papers, adding to a total of over 85 publications on its cancer diagnostic test, Signatera.
September 16, 2024 | 1:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Natera's stock is experiencing an upward trend due to the announcement of three new peer-reviewed papers on its Signatera cancer diagnostic test, which now has over 85 publications.
The publication of additional peer-reviewed papers enhances the credibility and perceived value of Natera's Signatera test, likely leading to increased investor confidence and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100